UNSPSC 51293611: Tipindole

This classification denotes a serotonin antagonist with the molecular formula C16H20N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier US65H9WBNH, chemically known as 1,3,4,5-tetrahydrothiopyrano(4,3-b)indole-8-carboxylic acid, 2-(dimethylamino)ethyl ester but generally known as tipindole, which bears US NIH Compound Identifier 65595. European Medicines Agency schedules Tipindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11104MIG.

UNSPSC 51293611 Tipindole is a Commodity code that appears in state and local procurement records primarily in connection with pharmaceutical and health-system purchasing, though the recent opportunities tagged under it show minimal direct alignment with tipindole specifically. The code surfaces in three recent solicitations: Seminole County, Florida's IFB for naloxone and drug deactivation systems; the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products. The actual purchasing activity reflects health agencies and state pharmacy benefit programs acquiring naloxone kits, pharmaceutical products through authorized wholesalers, and capability assessments for novel pharmacy-benefit contracting structures, rather than tipindole as a named product line. Issuing bodies include county health departments, state HHS agencies, and cooperative purchasing vehicles spanning multiple jurisdictions.

The geographic spread of recent activity centers on Florida, Texas, and Minnesota, with the MMCAP cooperative extending to Oregon and other participating states. The Seminole County solicitation (IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026, with pricing weighted at 75 percent and requiring distribution through AmerisourceBergen, Cardinal Health, or Morris & Dickson. The Texas HHS Commission RFI (HHS0017013, April 3, 2026) explores direct-to-manufacturer prescription fulfillment without traditional pharmacy benefit manager intermediaries. The code shows activity across state health departments and county systems but little evidence of tipindole-specific demand in current state and local solicitations.